KAMADA LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,939 ILa | -2.37% |
|
+1.57% | -12.93% |
| Mar. 06 | Transcript : Kamada Ltd., Q4 2023 Earnings Call, Mar 06, 2024 | |
| Mar. 06 | Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 573M 151M 57.34B | Sales 2025 * | 706M 186M 70.6B | Capitalization | 1.14B 301M 114B |
|---|---|---|---|---|---|
| Net income 2024 * | 46M 12.12M 4.6B | Net income 2025 * | 84M 22.13M 8.4B | EV / Sales 2024 * | 1.99 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.62 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 378 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| 1 day | -2.37% | ||
| 1 week | +1.57% | ||
| Current month | -5.92% | ||
| 1 month | -7.31% | ||
| 3 months | -7.89% | ||
| 6 months | +11.57% | ||
| Current year | -12.93% |
1 week
1 909.00
1 986.00
1 month
1 872.002 123.00
Current year
1 872.002 338.00
1 year
1 627.002 338.00
3 years
1 309.002 338.00
5 years
1 309.004 500.00
10 years
1 160.005 075.00
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 13-12-08 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 17-12-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 19-12-23 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1,939 | -2.37% | 15 707 |
| 24-04-24 | 1,986 | +2.80% | 23,877 |
| 24-04-21 | 1,932 | +1.20% | 10,106 |
| 24-04-18 | 1,909 | +1.33% | 29,387 |
| 24-04-17 | 1,884 | -1.62% | 102,551 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 06:27 am EDT
More quotes
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.93% | 302M | |
| -2.86% | 87.31B | |
| +3.95% | 40.86B | |
| -21.94% | 29.36B | |
| +55.70% | 24.49B | |
| -5.41% | 17.31B | |
| -44.23% | 11.26B | |
| -17.60% | 11.62B | |
| -13.96% | 11.31B | |
| +7.27% | 8.31B |
- Stock Market
- Equities
- KMDA Stock
